Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4765984 | 0.94 | PDE5A (0.30) | PDE5A | |
| SCHEMBL4767975 | 0.93 | TGFBR1 (0.30) | PDE5A | |
| SCHEMBL4764094 | 0.91 | MAPT (0.33) | — | |
| SCHEMBL4764078 | 0.91 | — | — | |
| Adipiplon SCHEMBL4543571 | 0.91 | — | — | |
| SCHEMBL4766506 | 0.90 | MAPT (0.33) | — | |
| SCHEMBL5258222 | 0.90 | MAPT (0.32) | — | |
| SCHEMBL4771805 | 0.89 | HSP90AB1 (0.35) | — | |
| SCHEMBL4769771 | 0.89 | — | — | |
| SCHEMBL4770055 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1880998-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2008-01-23 | — | — | EP | claimed |
| US-7271170-B2 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | claimed |
| EP-1648899-B1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2007-01-03 | — | — | EP | claimed |
| US-20050038043-A1 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-02-17 | — | — | US | claimed |
| US-20080139580-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139580-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139580-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1880998-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1880998-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7271170-B2 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271170-B2 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271170-B2 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1648899-B1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1648899-B1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20050038043-A1 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038043-A1 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | GABRA3, GABRA1, GABBR1 | PDE5A 1894/4885MEN1 4323/4885KMT2A 3001/4885 |
| US-20080139580-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | GABRA3, GABRA1, GABBR1 | PDE5A 1894/4885MEN1 4323/4885KMT2A 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.